Ferric Carboxymaltose in Patients with Heart Failure and Iron Deficiency
Open accessThe DOI matches its Crossref record; 25 of the 26 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Iron deficiency may impair aerobic performance. This study aimed to determine whether treatment with intravenous iron (ferric carboxymaltose) would improve symptoms in patients who had heart failure, reduced left ventricular ejection fraction, and iron deficiency, either with or without anemia. METHODS: We enrolled 459 patients with chronic heart failure of New York Heart Association (NYHA) functional class II or III, a left ventricular ejection fraction of 40% or less (for patients with NYHA class II) or 45% or less (for NYHA class III), iron deficiency (ferritin level <100 microg per liter or between 100 and 299 microg per liter, if the transferrin saturation was <20%), and a hemoglobin level of 95 to 135 g per liter. Patients were randomly assigned, in a 2:1 ratio, to receive 200 mg of intravenous iron (ferric carboxymaltose) or saline (placebo). The primary end points were the self-reported Patient Global Assessment and NYHA functional class, both at week 24. Secondary end points included the distance walked in 6 minutes and the health-related quality of life. RESULTS: Among the patients receiving ferric carboxymaltose, 50% reported being much or moderately improved, as compared with 28% of patients receiving placebo, according to the Patient Global Assessment (odds ratio for improvement, 2.51; 95% confidence interval [CI], 1.75 to 3.61). Among the patients assigned to ferric carboxymaltose, 47% had an NYHA functional class I or II at week 24, as compared with 30% of patients assigned to placebo (odds ratio for improvement by one class, 2.40; 95% CI, 1.55 to 3.71). Results were similar in patients with anemia and those without anemia. Significant improvements were seen with ferric carboxymaltose in the distance on the 6-minute walk test and quality-of-life assessments. The rates of death, adverse events, and serious adverse events were similar in the two study groups. CONCLUSIONS: Treatment with intravenous ferric carboxymaltose in patients with chronic heart failure and iron deficiency, with or without anemia, improves symptoms, functional capacity, and quality of life; the side-effect profile is acceptable. (ClinicalTrials.gov number, NCT00520780).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Likewise, parenteral iron substitution has been found to improve the clinical course of CHF in patients with coexisting ID [22–24].”
From Iron deficiency or anemia of inflammation?: Differential diagnosis and mechanisms of anemia of inflammation (2016) · cites this paper as [24]
In the citing paper
“We are aware that anemia is a complication of iron deficiency, though not the only one, since other tissues/organs may be iron-depleted before anemia develops, as occurs in chronic heart failure.75”
From Iron metabolism and iron disorders revisited in the hepcidin era (2020) · cites this paper as [75]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing
Benjamini, Y., & Hochberg, Y. (1995) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1995.tb02031.x · Cited by 109,482
EQ-SD: a measure of health status from the EuroQol Group
Rabin, R., & Charro, F. D. (2001) · Annals of Medicine · doi:10.3109/07853890109002087 · Cited by 5,613
Regression Models for Ordinal Data
McCullagh, P. (1980) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1980.tb01109.x · Cited by 4,453
2005 WRITING COMMITTEE MEMBERS, Hunt, S. A., Abraham, W. T., Chin, M. H., Feldman, A. M., Francis, G. S., Ganiats, T. G., Jessup, M., Konstam, M. A., Mancini, D. M., et al. (2009) · Circulation · doi:10.1161/circulationaha.109.192065 · Cited by 3,720
ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008
Dickstein, K., Authors/Task Force Members, Cohen-Solal, A., Filippatos, G., McMurray, J. J. V., Ponikowski, P., Poole-Wilson, P. A., Strömberg, A., van Veldhuisen, D. J., Atar, D., et al. (2008) · European Journal of Heart Failure · doi:10.1016/j.ejheart.2008.08.005 · Cited by 3,512
Self-citationGreen, C. P., Porter, C. B., Bresnahan, D. R., & Spertus, J. A. (2000) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(00)00531-3 · Cited by 1,827
Trends in Heart Failure Incidence and Survival in a Community-Based Population
Roger, V. L. (2004) · JAMA · doi:10.1001/jama.292.3.344 · Cited by 1,600
Jessup, M., & Brozena, S. (2003) · New England Journal of Medicine · doi:10.1056/nejmra021498 · Cited by 1,564
Hunt, S. A., Abraham, W. T., Chin, M. H., Feldman, A. M., Francis, G. S., Ganiats, T. G., Jessup, M., Konstam, M. A., Mancini, D. M., Michl, K., et al. (2009) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2008.11.013 · Cited by 1,374
Haas, J. D., & Brownlie, T. (2001) · The Journal of Nutrition · doi:10.1093/jn/131.2.676s · Cited by 1,186
Research works printed but not linked: 4
- Fairbanks V, Beutler E. Iron deficiency. In: Beutler E, ed. Williams hematology. 6th ed. New York: McGraw-Hill, 2001:295-304, 447-70.
- Davies KJ, 1982, Am J Physiol, 242, E418
- Usmanov RI, 2008, J Nephrol, 21, 236
- Ganzoni AM, 1970, Schweiz Med Wochenschr, 100, 301
Cited by
Items 301–400 of 1,002
Co-morbidities in heart failure
van Deursen, V. M., Damman, K., van der Meer, P., Wijkstra, P. J., Luijckx, G. J., van Beek, A. P., van Veldhuisen, D. J., & Voors, A. A. (2012) · Heart Failure Reviews · doi:10.1007/s10741-012-9370-7 · Cited by 87
Barish, C. F., Koch, T. A., Butcher, A., Morris, D., & Bregman, D. B. (2012) · Anemia · doi:10.1155/2012/172104 · Cited by 68
Chronic kidney disease, heart failure and neprilysin inhibition
Haynes, R., Zhu, D., Judge, P. K., Herrington, W. G., Kalra, P. A., & Baigent, C. (2019) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfz058 · Cited by 70
“Intravenous iron has been shown to improve functional capacity among patients with HFrEF and results of clinical outcomes trials are needed [46].”
BackgroundGrote Beverborg, N., van der Wal, H. H., Klip, I. T., Anker, S. D., Cleland, J., Dickstein, K., van Veldhuisen, D. J., Voors, A. A., & van der Meer, P. (2019) · JAMA Cardiology · doi:10.1001/jamacardio.2019.1739 · Cited by 65
Self-citationCardiorenal Syndrome: New Pathways and Novel Biomarkers
Gembillo, G., Visconti, L., Giusti, M. A., Siligato, R., Gallo, A., Santoro, D., & Mattina, A. (2021) · Biomolecules · doi:10.3390/biom11111581 · Cited by 86
“Several studies [44] have reported that patients treated with intravenous iron develop symptomatic improvement and increased exercise capacity independent of hemoglobin level effects.”
BackgroundFunctional iron deficiency and diastolic function in heart failure with preserved ejection fraction
Kašner, M., Aleksandrov, A. S., Westermann, D., Laßner, D., Gross, M. C., von Haehling, S., Anker, S. D., Schultheiß, H., & Tschöpe, C. (2013) · International Journal of Cardiology · doi:10.1016/j.ijcard.2013.07.185 · Cited by 74
Self-citationNoncardiac Comorbidities and Acute Heart Failure Patients
Mentz, R. J., & Felker, G. M. (2013) · Heart Failure Clinics · doi:10.1016/j.hfc.2013.04.003 · Cited by 65
Macdougall, I. C. (2009) · Current Medical Research and Opinion · doi:10.1185/03007990903512461 · Cited by 68
Adverse Outcome Prediction of Iron Deficiency in Patients with Acute Coronary Syndrome
Zeller, T., Waldeyer, C., Ojeda, F., Schnabel, R. B., Schäfer, S., Altay, A., Lackner, K. J., Anker, S. D., Westermann, D., Blankenberg, S., et al. (2018) · Biomolecules · doi:10.3390/biom8030060 · Cited by 69
“This definition of ID is commonly used in heart failure and was successfully validated in clinical trials [10].”
BackgroundMethodSelf-citationIron Deficiency in Chronic Heart Failure: Case-Based Practical Guidance
Lam, C. S. P., Doehner, W., & Colet, J. C. (2018) · ESC Heart Failure · doi:10.1002/ehf2.12333 · Cited by 72
“001 at Weeks 4, 12, and 24).(13) These findings are”
BackgroundSkeletal Muscle Abnormalities and Iron Deficiency in Chronic Heart Failure
Melenovský, V., Hlavatá, K., Šedivý, P., Dezortová, M., Borlaug, B. A., Petrák, J., Kautzner, J., & Hájek, M. (2018) · Circulation Heart Failure · doi:10.1161/circheartfailure.117.004800 · Cited by 71
Powers, J. M., & Buchanan, G. R. (2019) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2019.01.006 · Cited by 83
Calvet, X., Ruiz, M. Á. T., Dosal, A., Moreno, L., Parra, M. L., Figuerola, A., Suarez, D. L., Miquel, M., Villòria, A., & Gené, E. (2012) · PLoS ONE · doi:10.1371/journal.pone.0045604 · Cited by 64
Bömer, N., Pávez, M., Beverborg, N. G., Cleland, J. G. F., van Veldhuisen, D. J., & van der Meer, P. (2022) · Journal of Internal Medicine · doi:10.1111/joim.13456 · Cited by 70
“Several substantial, randomized, double-blind, placebo-controlled multicenter trials investigating intravenous (IV) iron—mainly with ferric carboxymaltose—in patients with HF and a reduced LVEF (HFrEF) have shown beneficial effects on symptoms, quality of life and exercise capacity [29–31].”
BackgroundValentová, M., Anker, S. D., & von Haehling, S. (2019) · Heart Failure Clinics · doi:10.1016/j.hfc.2019.08.006 · Cited by 74
Self-citationPreoperative anemia and postoperative outcomes after hepatectomy
Tohme, S. T., Varley, P. R., Landsittel, D. P., Chidi, A. P., & Tsung, A. (2015) · HPB · doi:10.1016/j.hpb.2015.09.002 · Cited by 70
Strauss, W., & Auerbach, M. (2018) · Patient Related Outcome Measures · doi:10.2147/prom.s169653 · Cited by 71
Iron Metabolism: An Emerging Therapeutic Target in Critical Illness
Litton, E., & Lim, J. (2019) · Critical Care · doi:10.1186/s13054-019-2373-1 · Cited by 73
Gutzwiller, F. S., Schwenkglenks, M. M., Blank, P. R., Braunhofer, P. G., Mori, C., Szucs, T. D., Ponikowski, P. P., & Anker, S. D. (2012) · European Journal of Heart Failure · doi:10.1093/eurjhf/hfs083 · Cited by 60
Self-citationEffects of intravenous iron on mononuclear cells during the haemodialysis session
Martín‐Malo, A., Merino, A. M., Carracedo, J., Alvarez-Lara, M. A., Ojeda, R., Soriano, S., Crespo, R., Ramı́rez, R., & Aljama, P. (2011) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfr711 · Cited by 62
Enjuanes, C., Bruguera, J., Grau, M., Cladellas, M., González, G., Meroño, O., Moliner, P., Verdú-Rotellar, J. M., Farré, N., & Colet, J. C. (2015) · Revista Española de Cardiología (English Edition) · doi:10.1016/j.rec.2015.08.018 · Cited by 81
Association of different iron deficiency cutoffs with adverse outcomes in chronic kidney disease
Eisenga, M. F., Nolte, I. M., van der Meer, P., Bakker, S. J. L., & Gaillard, S. (2018) · BMC Nephrology · doi:10.1186/s12882-018-1021-3 · Cited by 68
Richards, T., Breymann, C., Brookes, M., Lindgren, S. C., Macdougall, I. C., McMahon, L. P., Munro, M. G., Nemeth, E., Rosano, G. M. C., Schiefke, I., et al. (2021) · Annals of Medicine · doi:10.1080/07853890.2020.1867323 · Cited by 67
Redefining Iron Deficiency in Patients With Chronic Heart Failure
Packer, M., Anker, S. D., Butler, J., Cleland, J. G. F., Kalra, P. R., Mentz, R. J., Ponikowski, P. P., & Talha, K. M. (2024) · Circulation · doi:10.1161/circulationaha.124.068883 · Cited by 76
Self-citationGaber, R., Kotb, N. A., Ghazy, M., Nagy, H. M., Salama, M., & Elhendy, A. (2011) · Echocardiography · doi:10.1111/j.1540-8175.2011.01532.x · Cited by 62
Toblli, J. E., & Angerosa, M. (2014) · Drug Design Development and Therapy · doi:10.2147/dddt.s55499 · Cited by 77
Comorbidities in Heart Failure
van der Wal, H. H., van Deursen, V. M., van der Meer, P., & Voors, A. A. (2017) · Handbook of experimental pharmacology · doi:10.1007/164_2017_27 · Cited by 74
Ferric Carboxymaltose: A Review in Iron Deficiency
Scott, L. J. (2018) · Drugs · doi:10.1007/s40265-018-0885-7 · Cited by 68
The Treatment of Heart Failure with Reduced Ejection Fraction
Berliner, D., Hänselmann, A., & Bauersachs, J. K. (2020) · Deutsches Ärzteblatt international · doi:10.3238/arztebl.2020.0376 · Cited by 78
Anemia of Chronic Disease in Patients With Cardiovascular Disease
Lanser, L., Fuchs, D., Scharnagl, H., Grammer, T. B., Kleber, M. E., März, W., Weiß, G., & Kurz, K. (2021) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2021.666638 · Cited by 76
“classifications (9, 33), those patients were not classified as having ACD because TSAT was above 20%.”
BackgroundIron deficiency in critically ill patients: highlighting the role of hepcidin
Heming, N., Montravers, P., & Lasocki, S. (2011) · Critical Care · doi:10.1186/cc9992 · Cited by 72
McMurray, J. J. V., Docherty, K. F., de Boer, R. A., Hammarstedt, A., Kitzman, D. W., Kosiborod, M. N., Maria Langkilde, A., Reicher, B., Senni, M., Shah, S. J., et al. (2024) · Circulation · doi:10.1161/circulationaha.123.065061 · Cited by 60
Graham, F. J., Masini, G., Pellicori, P., Cleland, J. G. F., Greenlaw, N., Friday, J. M., Kazmi, S., & Clark, A. L. (2021) · European Journal of Heart Failure · doi:10.1002/ejhf.2251 · Cited by 73
Anemia in heart failure - from guidelines to controversies and challenges
Sîrbu, O., Floria, M., Dăscălița, P., Stoica, A., Adascalitei, P., Șorodoc, V., & Șorodoc, L. (2018) · The Anatolian Journal of Cardiology · doi:10.14744/anatoljcardiol.2018.08634 · Cited by 75
“Several studies (39-45) have been set out to establish the effect of injectable iron treatment in patients with HF (Table 1).”
BackgroundAlcaide-Aldeano, A., Garay, A., Alcoberro, L., Jiménez‐Marrero, S., Yun, S., Tajes, M., García‐Romero, E., Díez‐López, C., González‐Costello, J., Mateus-Porta, G., et al. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9041199 · Cited by 64
“On the other hand, the association of the classic definition of the FAIR-HF study [24] (ferritin <100 ng/mL or 100–300 ng/mL with TSAT <20%) with exercise capacity was weaker (β = −23.”
BackgroundPavlovic, N. V., GILOTRA, N. A., LEE, C. S., NDUMELE, C., MAMMOS, D., DENNISONHIMMELFARB, C., & AbshireSaylor, M. (2022) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2021.07.005 · Cited by 58
Iron Deficiency: A New Target for Patients With Heart Failure
Rizzo, C., Carbonara, R., Ruggieri, R., Passantino, A., & Scrutinio, D. (2021) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2021.709872 · Cited by 71
Myles, P. S., Richards, T., Klein, A. A., Wood, E. M., Wallace, S. K. A., Shulman, M. A., Martin, C., Bellomo, R., Corcoran, T. B., Peyton, P. J., et al. (2022) · British Journal of Anaesthesia · doi:10.1016/j.bja.2022.06.014 · Cited by 58
Increased Heme Levels in the Heart Lead to Exacerbated Ischemic Injury
Sawicki, K. T., Shang, M., Wu, R., Chang, H., Khechaduri, A., Sato, T., Kamide, C., Liu, T., Prasad, S. V. N., & Ardehali, H. (2015) · Journal of the American Heart Association · doi:10.1161/jaha.115.002272 · Cited by 63
Intravenous iron therapy in non‐anemic iron‐deficient menstruating adolescent females with fatigue
Sharma, R., Stanek, J. R., Koch, T. L., Grooms, L., & O'Brien, S. H. (2016) · American Journal of Hematology · doi:10.1002/ajh.24461 · Cited by 58
Management of anemia in patients with congestive heart failure
Tim Goodnough, L., Comin‐Colet, J., Leal‐Noval, S., Ozawa, S., Takere, J., Henry, D., Javidroozi, M., Hohmuth, B., Bisbe, E., Gross, I., et al. (2017) · American Journal of Hematology · doi:10.1002/ajh.24595 · Cited by 58
Edelmann, F., Feuerstein, A., Gelbrich, G., Hasenfuss, G. P., Herrmann‐Lingen, C., Duvinage, A., Schwarz, S., Mende, M., Prettin, C., Trippel, T. D., et al. (2017) · European Journal of Heart Failure · doi:10.1002/ejhf.862 · Cited by 63
Wilson, M., Dekker, J. W. T., Bruns, E. R. J., Borstlap, W. A. A., Jeekel, J. J., Zwaginga, J. J., & Schipperus, M. R. (2017) · Transfusion · doi:10.1111/trf.14456 · Cited by 66
Impact of Nutrition on Pulmonary Arterial Hypertension
Callejo, M., Barberà, J. A., Duarte, J., & Pérez‐Vizcaíno, F. (2020) · Nutrients · doi:10.3390/nu12010169 · Cited by 64
“Consequently, the clinical manifestation is shorter 6MWD. Interestingly, restoring iron levels in patients with chronic left heart failure significantly improves 6MWD and New York Heart Association (NYHA)-Functional Class [78,79].”
BackgroundInfluentialQian, C., Wei, B., Ding, J., Wu, H., & Wang, Y. (2015) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2015.06.009 · Cited by 63
Moliner, P., Enjuanes, C., Tajes, M., Cainzos‐Achirica, M., Lupón, J., Garay, A., Jiménez‐Marrero, S., Yun, S., Farré, N., Cladellas, M., et al. (2019) · Journal of the American Heart Association · doi:10.1161/jaha.118.010887 · Cited by 71
Anker, S. D., Khan, M. S., Butler, J., von Haehling, S., Jankowska, E. A., Ponikowski, P. P., & Friede, T. (2023) · European Journal of Heart Failure · doi:10.1002/ejhf.2860 · Cited by 60
Self-citationIntravenous ferric carboxymaltose for the treatment of iron deficiency anemia
Friedrisch, J. R., & Cançado, R. D. (2015) · Revista Brasileira de Hematologia e Hemoterapia · doi:10.1016/j.bjhh.2015.08.012 · Cited by 78
Florian, A. R., Ludwig, A., Rösch, S., Yildiz, H., Klumpp, S., Sechtem, U. P., & Yılmaz, A. (2014) · International Journal of Cardiology · doi:10.1016/j.ijcard.2014.02.016 · Cited by 57
Exercise: a “new drug” for elderly patients with chronic heart failure
Antonicelli, R., Spazzafumo, L., Scalvini, S., Olivieri, F., Matassini, M. V., Parati, G., Sindaco, D. D., Gallo, R., & Lattanzio, F. (2016) · Aging · doi:10.18632/aging.100901 · Cited by 67
Qassim, A., Grivell, R. M., Henry, A., Kidson‐Gerber, G., Shand, A., & Grzeskowiak, L. E. (2019) · The Medical Journal of Australia · doi:10.5694/mja2.50308 · Cited by 58
Anaemia, iron homeostasis and pulmonary hypertension: a review
Sonnweber, T., Pizzini, A., Tancevski, I., Löffler-Ragg, J., & Weiss, G. (2020) · Internal and Emergency Medicine · doi:10.1007/s11739-020-02288-1 · Cited by 57
Lewis, G. D., Semigran, M. J., Givertz, M. M., Malhotra, R. K., Anstrom, K. J., Hernandez, A. F., Shah, M., & Braunwald, E. (2016) · Circulation Heart Failure · doi:10.1161/circheartfailure.115.000345 · Cited by 65
2026 ESC Guidelines for the management of heart failure
Køber, L., Adamo, M., Ruwald, A., Tomasoni, D., Anderson, L., Andersson, C., Brugts, J. J., Chioncel, O. D., Donal, E., Ferdinandy, P., et al. (2026) · European Heart Journal · doi:10.1093/eurheartj/ehag100 · Cited by 167
Chung, Y. J., Luo, A., Park, K. C., Loonat, A. A., Lakhal‐Littleton, S., Robbins, P. A., & Swietach, P. (2019) · JCI Insight · doi:10.1172/jci.insight.125618 · Cited by 58
“with ferric carboxymaltose (FCM), a formulation used clinically in humans (6).”
Iron Supplementation Improves Cardiovascular Outcomes in Patients with Heart Failure
Zhou, X., Xu, W., Xu, Y., & Qian, Z. (2019) · The American Journal of Medicine · doi:10.1016/j.amjmed.2019.02.018 · Cited by 59
Exercise-Induced Changes in Iron Status and Hepcidin Response in Female Runners
Auersperger, I., Škof, B., Leskošek, B., Knap, B., Jerin, A., & Lainscak, M. (2013) · PLoS ONE · doi:10.1371/journal.pone.0058090 · Cited by 55
Lasocki, S., Chudeau, N., Papet, T., Tartière, D., Roquilly, A., Carlier, L., Mimoz, O., Séguin, P., Mallédant, Y., Asehnoune, K., et al. (2014) · Critical Care · doi:10.1186/s13054-014-0542-9 · Cited by 58
Iron deficiency, anemia, and mortality in renal transplant recipients
Eisenga, M. F., Minović, I., Berger, S. P., Kootstra‐Ros, J. E., van den Berg, E., Riphagen, I. J., Navis, G., van der Meer, P., Bakker, S. J. L., & Gaillard, S. (2016) · Transplant International · doi:10.1111/tri.12821 · Cited by 66
Heme: The Lord of the Iron Ring
Voltarelli, V. A., de Souza, R. W. A., Miyauchi, K., Hauser, C. J., & Otterbein, L. E. (2023) · Antioxidants · doi:10.3390/antiox12051074 · Cited by 58
“Intravenous iron has been suggested to provide clinical benefit in iron-deficient patients with chronic systolic heart failure [140,141].”
BackgroundIron replacement therapy in the routine management of blood donors
Bryant, B. J., Yau, Y. Y., Arceo, S. M., Daniel‐Johnson, J. A., Hopkins, J. A., & Leitman, S. F. (2011) · Transfusion · doi:10.1111/j.1537-2995.2011.03488.x · Cited by 60
Use of intravenous iron supplementation in chronic kidney disease: an update.
Macdougall, I. C., & Geisser, P. (2013) · Iranian Journal of Kidney Diseases · Cited by 65
Patient Blood Management as Standard of Care
Shander, A., Bracey, A., Goodnough, L. T., Gross, I., Hassan, N. E., Ozawa, S. J., & Marques, M. B. (2016) · Anesthesia & Analgesia · doi:10.1213/ane.0000000000001496 · Cited by 54
Yeo, T. J., Yeo, P. S. D., Hadi, F. A., Cushway, T., Lee, K. Y., Yin, F. F., Ching, A., Li, R., Loh, S. Y., Lim, S. L., et al. (2018) · ESC Heart Failure · doi:10.1002/ehf2.12250 · Cited by 54
“It was followed by the Beneficial Effects of Long-term Intravenous Iron Therapy with Ferric Carboxymaltose in Patients with Symptomatic Heart Failure and Iron Deficiency (CONFIRMHF) trial, consolidating these findings as well as proving the sustainability of these outcomes over 1 year.(8,9) Results from these trials h…”
BackgroundWang, K., Li, L., Xu, X., Lu, L., Wang, J., Wang, S., Wang, Y., Jin, Z., Zhang, J. Z., & Jiang, Y. (2019) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.8b18648 · Cited by 61
Schrage, B., Rübsamen, N., Schulz, A., Münzel, T. F., Pfeiffer, N., Wild, P. S., Beutel, M. E., Schmidtmann, I. M., Lott, R., Blankenberg, S., et al. (2020) · Clinical Research in Cardiology · doi:10.1007/s00392-020-01631-y · Cited by 66
Iron deficiency for prognosis in acute coronary syndrome – A systematic review and meta-analysis
Reinhold, J., Papadopoulou, C., Baral, R., & Vassiliou, V. S. (2020) · International Journal of Cardiology · doi:10.1016/j.ijcard.2020.12.021 · Cited by 56
Rangel, I., Gonçalves, A., Sousa, C., Leite, S., Campelo, M., Martins, E., Amorim, S., Moura, B., Silva‐Cardoso, J., & Maciel, M. J. (2014) · Cardiology · doi:10.1159/000358377 · Cited by 57
Núñez, J. E., Núñez, E., Rizopoulos, D., Miñana, G., Bodı́, V., Bondanza, L., Hüsser, O., Merlos, P., Santas, E., Pascual-Figal, D. A., et al. (2013) · Circulation Journal · doi:10.1253/circj.cj-13-0630 · Cited by 53
Liver dysfunction and its nutritional implications in heart failure
Valentová, M., von Haehling, S., Doehner, W., Murín, J., Anker, S. D., & Sandek, A. (2012) · Nutrition · doi:10.1016/j.nut.2012.06.002 · Cited by 59
Self-citationDietary Iron Restriction Prevents Hypertensive Cardiovascular Remodeling in Dahl Salt-Sensitive Rats
Naito, Y., Hirotani, S., Sawada, H., Akahori, H., Tsujino, T., & Masuyama, T. (2011) · Hypertension · doi:10.1161/hypertensionaha.110.159681 · Cited by 54
Anemia and coronary artery disease: pathophysiology, prognosis, and treatment
Rymer, J. A., & Rao, S. V. (2017) · Coronary Artery Disease · doi:10.1097/mca.0000000000000598 · Cited by 62
García‐Escobar, A., Lázaro-García, R., Goicolea-Ruigómez, J., González‐Casal, D., Fontenla, A., Soto, N., González‐Panizo, J., Datino, T., Pizarro, G., Moreno, R., et al. (2024) · High Blood Pressure & Cardiovascular Prevention · doi:10.1007/s40292-024-00662-0 · Cited by 64
“This notwithstanding, considerable evidence supports the improvement of NYHA functional class from the iron replacement in patients with HF and iron deficiency [62–64].”
Ponikowski, P. P., van Veldhuisen, D. J., Colet, J. C., Ertl, G., Komajda, M., VIu, M., McDonagh, T. A., Parkhomenko, A. N., Tavazzi, L., Levesque, V., et al. (2014) · ESC Heart Failure · doi:10.1002/ehf2.12006 · Cited by 58
Self-citationMetabolic abnormalities of the heart in type II diabetes
Amaral, N., & Okonko, D. O. (2015) · Diabetes and Vascular Disease Research · doi:10.1177/1479164115580936 · Cited by 63
Auersperger, I., Knap, B., Jerin, A., Blagus, R., Lainscak, M., Skitek, M., & Skof, B. (2012) · International Journal of Sport Nutrition and Exercise Metabolism · doi:10.1123/ijsnem.22.1.55 · Cited by 52
Rheude, T. A., Pellegrini, C., Michel, J., Trenkwalder, T., Mayr, N. P., Kessler, T., Kasel, A. M., Schunkert, H., Kastrati, A., Hengstenberg, C., et al. (2017) · International Journal of Cardiology · doi:10.1016/j.ijcard.2017.06.024 · Cited by 55
Molecular Changes in Myocardium in the Course of Anemia or Iron Deficiency
Jankowska, E. A., & Ponikowski, P. P. (2010) · Heart Failure Clinics · doi:10.1016/j.hfc.2010.03.003 · Cited by 56
Self-citationMiles, L. F., Kunz, S. A., Na, L. H., Braat, S., Burbury, K., & Story, D. A. (2018) · Anaesthesia · doi:10.1111/anae.14115 · Cited by 51
Ponikowski, P. P., Kirwan, B., Anker, S. D., Dorobanţu, M., Dróżdż, J., Fabien, V., Filippatos, G. S., Haboubi, T., Keren, A., Khintibidze, I., et al. (2019) · European Journal of Heart Failure · doi:10.1002/ejhf.1710 · Cited by 58
Self-citationSalah, H. M., Savarese, G., Rosano, G. M. C., Ambrosy, A. P., Mentz, R. J., & Fudim, M. (2023) · ESC Heart Failure · doi:10.1002/ehf2.14310 · Cited by 55
Cooper, T. J., Guazzi, M., Al‐Mohammad, A., Amir, O., Gal, T. B., Cleland, J. G. F., & Dickstein, K. (2012) · European Journal of Heart Failure · doi:10.1093/eurjhf/hfs152 · Cited by 51
Self-citationNovel therapies in acute and chronic heart failure
Aronson, D., & Krum, H. (2012) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2012.03.002 · Cited by 55
Structural and functional abnormalities in iron-depleted heart
Kobak, K. A., Radwańska, M., Dzięgała, M., Kasztura, M., Josiak, K., Banasiak, W., Ponikowski, P. P., & Jankowska, E. A. (2018) · Heart Failure Reviews · doi:10.1007/s10741-018-9738-4 · Cited by 55
Self-citationForte, M., Palmerio, S., Bianchi, F., Volpe, M., & Rubattu, S. D. (2019) · Journal of Molecular Medicine · doi:10.1007/s00109-019-01771-3 · Cited by 55
Correale, M., Paolillo, S., Mercurio, V., Limongelli, G., Barillà, F., Ruocco, G. M., Palazzuoli, A., Scrutinio, D., Lagioia, R., Lombardi, C., et al. (2019) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2019.10.008 · Cited by 59
Safety of intravenous iron use in chronic kidney disease
Kalra, P. A., & Bhandari, S. (2016) · Current Opinion in Nephrology and Hypertension · doi:10.1097/mnh.0000000000000263 · Cited by 50
Iron Deficiency in Heart Failure: A Practical Guide
Ebner, N., & von Haehling, S. (2013) · Nutrients · doi:10.3390/nu5093730 · Cited by 57
Experience with intravenous ferric carboxymaltose in patients with iron deficiency anemia
Bregman, D. B., & Goodnough, L. T. (2014) · Therapeutic Advances in Hematology · doi:10.1177/2040620714521127 · Cited by 61
Management of Anemia in Patients with Inflammatory Bowel Disease (IBD)
Patel, D., Trivedi, C. P., & Khan, N. H. (2018) · Current Treatment Options in Gastroenterology · doi:10.1007/s11938-018-0174-2 · Cited by 60
Iron deficiency screening is a key issue in chronic inflammatory diseases: A call to action
Cacoub, P., Choukroun, G. J., Solal, A. C., Luporsi, É., Peyrin‐Biroulet, L., Peoc’h, K., Andrieu, V., Lasocki, S., Puy, H., & Trochu, J. (2022) · Journal of Internal Medicine · doi:10.1111/joim.13503 · Cited by 72
Jung, C., Fujita, B., Lauten, A., Kiehntopf, M., Küthe, F., Ferrari, M. W., & Figulla, H. (2011) · International Journal of Cardiology · doi:10.1016/j.ijcard.2011.08.052 · Cited by 49
Yamauchi, T., Sakata, Y., Takada, T., Nochioka, K., Miura, M., Tadaki, S., Ushigome, R., Sato, K., Onose, T., Tsuji, K., et al. (2015) · Circulation Journal · doi:10.1253/circj.cj-15-0174 · Cited by 54
Silverberg, D. S. (2011) · Heart Failure Reviews · doi:10.1007/s10741-010-9194-2 · Cited by 48
“This suggestion gains added impetus as a result of a recent study using IV ferric carboxymaltose, the FAIR-HF study [38], a large randomized placebo-”
Rosano, G. M. C., Vitale, C., Adamo, M., & Metra, M. (2021) · Journal of Cardiovascular Medicine · doi:10.2459/jcm.0000000000001221 · Cited by 55
Iron Deficiency and Anaemia in Heart Failure: Understanding the FAIR-HF Trial
González‐Costello, J., & Colet, J. C. (2010) · European Journal of Heart Failure · doi:10.1093/eurjhf/hfq165 · Cited by 48
Anemia in Heart Failure Patients
Alexandrakis, M. G., & Tsirakis, G. (2012) · ISRN Hematology · doi:10.5402/2012/246915 · Cited by 55
Drozd, M., Jankowska, E. A., Banasiak, W., & Ponikowski, P. P. (2016) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-016-0211-2 · Cited by 56
Self-citationGraham, F. J., Pellicori, P., Ford, I., Petrie, M. C., Kalra, P. R., & Cleland, J. G. F. (2021) · Clinical Research in Cardiology · doi:10.1007/s00392-021-01837-8 · Cited by 49
Chapter 2: Use of iron to treat anemia in CKD
(2012) · Kidney International Supplements · doi:10.1038/kisup.2012.34 · Cited by 53
Metadata
- Authors
- Anker, S. D., Comin Colet, J., Filippatos, G., Willenheimer, R., Dickstein, K., Drexler, H., Lüscher, T. F., Bart, B., Banasiak, W., Niegowska, J., Kirwan, B.-A., Mori, C., von Eisenhart Rothe, B., Pocock, S. J., Poole-Wilson, P. A., & Ponikowski, P.
- Affiliations
- Stavanger University Hospital (NO)
- Lund University (SE)
- University of Bergen (NO)
- Medizinische Hochschule Hannover (DE)
- University Hospital Zurich (CH)
- Pirogov Russian National Research Medical University (RU)
- State Oil Company of Azerbaijan Republic (Azerbaijan) (AZ)
- Vifor Pharma (Switzerland) (CH)
- London School of Hygiene & Tropical Medicine (GB)
- Imperial College London (GB)
- Wroclaw Medical University (PL)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2009-12-17
- Volume
- 361
- Issue
- 25
- Pages
- 2436-2448
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2148669301
- Cited by
- 2,083
- References
- 26
- Citations by year
- 2026: 101 · 2025: 131 · 2024: 145 · 2023: 156 · 2022: 162 · 2021: 190 · 2020: 128 · 2019: 129 · 2018: 113 · 2017: 133 · 2016: 101 · 2015: 115 · 2014: 102 · 2013: 93 · 2012: 106
- FWCI
- 62.22
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Zurich Open Repository and Archive (University of Zurich) (acceptedVersion, other-oa)
- LSHTM Research Online (London School of Hygiene and Tropical Medicine) (acceptedVersion)
- ABACUS. Repositorio de Producción Científica (Universidad Europea) (submittedVersion, other-oa)
- Dipòsit Digital de la Universitat de Barcelona (Universitat de Barcelona) (submittedVersion, public-domain)
- LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) (submittedVersion, other-oa)
- Lund University Publications (Lund University) (submittedVersion, other-oa)
- University of Bedfordshire Repository (University of Bedfordshire) (submittedVersion)
- Zurich Open Repository and Archive (University of Zurich) (submittedVersion, other-oa)
- Zurich Open Repository and Archive (University of Zurich)
- Funders
- Amgen
- Teva Pharmaceutical Industries
- Vifor Pharma
- Servier
- Topics
- Health Sciences › Medicine › Hematology › Iron Metabolism and Disorders
- Health Sciences › Medicine › Hematology › Erythropoietin and Anemia Treatment
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
- Keywords
- ferric carboxymaltose, intravenous iron, chronic heart failure, iron deficiency, anemia, reduced left ventricular ejection fraction, NYHA functional class, symptom improvement, functional capacity, 6-minute walk test, health-related quality of life, ferritin, transferrin saturation, adverse events, mortality, serious adverse events, iron deficiency anemia
- MeSH terms
- Iron Deficiencies, Aged, Chronic Disease, Female, Ferric Compounds, Ferritins, Follow-Up Studies, Heart Failure, Hematinics, Humans, Male, Maltose, Quality of Life, Stroke Volume, Ventricular Dysfunction, Left, Anemia, Iron-Deficiency
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.